Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial

Published:2024-01 Issue: Volume:67 Page:102359
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Zhan Yangqing,Lin Zhengshi,Liang Jingyi,Sun Ruilin,Li Yueping,Lin Bingliang,Ge Fangqi,Lin Ling,Lu Hongzhou^ORCID,Su Liang,Xiang Tianxin,Pan Hongqiu,Huang Chaolin,Deng Ying,Wang Furong,Xu Ruhong,Chen Dexiong,Zhang Ping,Tong Jianlin,Wang Xifu,Meng Qingwei,Zheng Zhigang,Ou Shuqiang,Guo Xiaoyun,Yao Herui,Yu Tao,Li Weiyang,Zhang Yu,Jiang Mei^ORCID,Fang Zhonghao,Song Yudi,Chen Ruifeng,Luo Jincan,Kang Changyuan,Liang Shiwei,Li Haijun^ORCID,Zheng Jingping,Zhong Nanshan,Yang Zifeng^ORCID,Yanming Huang,Haiping Dong,Hou Jinlin,Lei Shao,Xiaoguang Li,Yan Gao

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England;Davies;Science,2021

2. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies;Cao;Nature,2022

3. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection;Cao;Nature,2022

4. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron;Cui;Cell,2022

5. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5;Wang;Nature,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease;European Journal of Medicinal Chemistry;2024-10

2. Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics;Acta Pharmaceutica Sinica B;2024-09

3. Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19;Frontiers in Pharmacology;2024-08-28

4. Nirmatrelvir for Adult Outpatients with Covid-19;New England Journal of Medicine;2024-08

5. 3-chymotrypsin-like protease in SARS-CoV-2;Bioscience Reports;2024-08